These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 30431741)

  • 1. Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors´ treatment: Spectrum of imaging appearances.
    Malikova H; Holesta M; Fialova A; Arenbergerova M; Weichet J
    Neuro Endocrinol Lett; 2018 Sep; 39(3):196-204. PubMed ID: 30431741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy-induced autoimmune hypophysitis.
    Valecha G; Pant M; Ibrahim U; Atallah JP
    J Oncol Pharm Pract; 2019 Jan; 25(1):217-220. PubMed ID: 28825378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.
    Lam T; Chan MM; Sweeting AN; De Sousa SM; Clements A; Carlino MS; Long GV; Tonks K; Chua E; Kefford RF; Chipps DR
    Intern Med J; 2015 Oct; 45(10):1066-73. PubMed ID: 26010858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoimmune hypophysitis.
    Ileana-Dumbrava E; Subbiah V
    Lancet Oncol; 2018 Feb; 19(2):e123. PubMed ID: 29413466
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival.
    Johnson J; Goldner W; Abdallah D; Qiu F; Ganti AK; Kotwal A
    J Natl Compr Canc Netw; 2023 Feb; 21(3):281-287. PubMed ID: 36828029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
    Nogueira E; Menon A; Dede A; Mitra I; Brock C; Larkin J; Morganstein D
    Curr Probl Cancer; 2021 Dec; 45(6):100710. PubMed ID: 33622518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis.
    Chodakiewitz Y; Brown S; Boxerman JL; Brody JM; Rogg JM
    Clin Neurol Neurosurg; 2014 Oct; 125():125-30. PubMed ID: 25127260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
    Wachsmann JW; Ganti R; Peng F
    Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab-Induced Autoimmune Hypophysitis: Diagnostic and Management Challenges Illustrated by a Clinical Case.
    Marques P; Grossman A
    Acta Med Port; 2015; 28(6):775-9. PubMed ID: 27265913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
    Juszczak A; Gupta A; Karavitaki N; Middleton MR; Grossman AB
    Eur J Endocrinol; 2012 Jul; 167(1):1-5. PubMed ID: 22495490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypophysitis secondary to pembrolizumab: a case report and review of the literature.
    Montero Pérez O; Sánchez Escudero L; Guzmán Ramos MI; Aviñó Tarazona V
    Anticancer Drugs; 2022 Jan; 33(1):94-99. PubMed ID: 34261922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab Induced Hypophysitis: MRI Findings in a Series of 3 Cases.
    Wadhwa V
    J Ark Med Soc; 2017 May; 113(11):270-272. PubMed ID: 30351740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction.
    Hartmann A; Paparoupa M; Volkmer BG; Rompel R; Wittig A; Schuppert F
    J Oncol Pharm Pract; 2020 Oct; 26(7):1774-1779. PubMed ID: 32164491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential occurrence of primary and secondary hypothyroidism during treatment with nivolumab: pitfalls in immuno-oncological therapy and endocrinological diagnostic procedures.
    Ansorge C; Seufert J; Meiss F; von Bubnoff D
    J Dtsch Dermatol Ges; 2018 Dec; 16(12):1483-1485. PubMed ID: 30411844
    [No Abstract]   [Full Text] [Related]  

  • 15. Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management.
    Tiu C; Pezaro C; Davis ID; Grossmann M; Parente P
    Asia Pac J Clin Oncol; 2015 Jun; 11(2):190-4. PubMed ID: 25855890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
    Hammami MB; Gill R; Thiruvengadam N; Oh DY; Beck K; Mahadevan U; Kattah MG
    Dig Dis Sci; 2019 Mar; 64(3):685-688. PubMed ID: 30778872
    [No Abstract]   [Full Text] [Related]  

  • 17. Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.
    Siddiqui MS; Lai ZM; Spain L; Greener V; Turajlic S; Larkin J; Morganstein DL
    J Endocrinol Invest; 2021 Jan; 44(1):195-203. PubMed ID: 32449093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab-induced hypophysitis and ileocolitis: Serial pituitary MRI findings.
    Singh D; Hsu CC; Kwan GN; Bhuta S
    Neurol India; 2017; 65(1):165-166. PubMed ID: 28084260
    [No Abstract]   [Full Text] [Related]  

  • 19. Ipilimumab-induced hypophysitis: review of the literature.
    Araujo PB; Coelho MC; Arruda M; Gadelha MR; Neto LV
    J Endocrinol Invest; 2015 Nov; 38(11):1159-66. PubMed ID: 25957829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgG4-related hypophysitis in patients with autoimmune pancreatitis.
    Kanie K; Bando H; Iguchi G; Shiomi H; Masuda A; Fukuoka H; Nishizawa H; Fujita Y; Sakai A; Kobayashi T; Shiomi Y; Yoshida K; Matsumoto R; Suda K; Kodama Y; Ogawa W; Takahashi Y
    Pituitary; 2019 Feb; 22(1):54-61. PubMed ID: 30607745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.